Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SUPERIORITY OF SEQUENTIAL VERSUS CONCURRENT ADMINISTRATION OF PACLITAXEL WITH ETOPOSIDE IN ADVANCED NONSMALL CELL LUNG-CANCER - COMPARISON OF 2 PHASE-II TRIALS
Autore:
FELIP E; MASSUTI B; CAMPS C; BENITO D; ISLA D; GONZALEZLARRIBA JL; LOPEZCABRERIZO MP; SALAMANCA O; PUERTOPICA J; MOYANO A; BASELGA J; ROSELL R;
Indirizzi:
HOSP GERMANS TRIAS & PUJOL,MED ONCOL SERV,BOX 72 BARCELONA 08916 SPAIN HOSP GEN VALLE HEBRON,DEPT MED ONCOL BARCELONA 08035 SPAIN HOSP GEN ALICANTE ALICANTE 03010 SPAIN HOSP GEN VALENCIA VALENCIA 46014 SPAIN BRISTOL MYERS SQUIBB CO MADRID 28040 SPAIN UNIV ZARAGOZA,HOSP CLIN ZARAGOZA 50009 SPAIN HOSP CLIN SAN CARLOS MADRID 28040 SPAIN HOSP GERMANS TRIAS & PUJOL BARCELONA 08916 SPAIN HOSP INFANTA CRISTINA BADAJOZ 06080 SPAIN HOSP RAMON Y CAJAL E-28034 MADRID SPAIN
Titolo Testata:
Clinical cancer research
fascicolo: 11, volume: 4, anno: 1998,
pagine: 2723 - 2728
SICI:
1078-0432(1998)4:11<2723:SOSVCA>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
METASTATIC BREAST-CANCER; CISPLATIN-CONTAINING REGIMENS; COLONY-STIMULATING FACTOR; CYTOCHROME-P450 3A4; 3-HOUR INFUSION; TUMOR-CELLS; IN-VITRO; COMBINATION; TAXOL; CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
38
Recensione:
Indirizzi per estratti:
Citazione:
E. Felip et al., "SUPERIORITY OF SEQUENTIAL VERSUS CONCURRENT ADMINISTRATION OF PACLITAXEL WITH ETOPOSIDE IN ADVANCED NONSMALL CELL LUNG-CANCER - COMPARISON OF 2 PHASE-II TRIALS", Clinical cancer research, 4(11), 1998, pp. 2723-2728

Abstract

Paclitaxel and etoposide are two chemotherapy agents with broad cytotoxic activity and different mechanisms of action and resistance, Preclinical studies of their combined cytotoxicity have yielded conflictingresults, We performed two sequential Phase II trials using different sequence schedules of paclitaxel and etoposide as first-line treatmentin advanced non-small cell lung cancer (NSCLC), Forty-four patients with stage IIIB or IV NSCLC were included between July 1995 and September 1996, All patients received etoposide at 100 mg/m(2), given as an i.v. infusion on days 1, 2, and 3, The first 20 patients (part A) also received paclitaxel at 175 mg/m(2) as a 3-h infusion on day 1, immediately prior to etoposide, The subsequent 24 patients (part B) were given the same paclitaxel dose, but on day 4, Grade 3-4 granulocytopenia was seen in 70% of the patients in part A and in 37% of those in part 70% (P = 0,04), Twenty-five % of the courses in part A and 4% of the courses in part B were associated with granulocyte nadir less than or equal to 500/mu l (P = 0.00006), No responses were observed in part A, although disease was stabilized in 14 patients (70%), In part B, there were two complete responses and seven partial responses, for an overall response rate of 37.5% (95% confidence interval, 21-58%), In conclusion, toxicity and antitumor activity of the paclitaxel/etoposide combination may be sequence dependent. Our findings suggest that etoposide followed by paclitaxel is well tolerated and has greater activity in NSCLC than concurrent administration.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 06:22:14